BIOANALYTICAL SYSTEMS,INC. (NASDAQ:BASI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of February 11, 2019, the Board of Directors of Bioanalytical Systems, Inc. (the “Company”) elected Daniel Thomas Oakley, age 61, Chief Operating Officer of the Company.
Mr. Oakley previously served as Chief Executive Officer of Seventh Wave Laboratories, LLC, a subsidiary of the Company. Mr. Oakley also served in that role from January 2018 through the Company’s acquisition of Seventh Wave Laboratories’ consulting-based contract research laboratory operations in July of 2018. From 2015 to 2017, Mr. Oakley held the position of Chief Executive Officer of DTO Associates, LLC, a private consulting company which advised companies on strategic concerns. Prior to his tenure at DTO Associates, LLC, Mr. Oakley was employed as President and Chief Operating Officer of MPI Research, Inc., a non-clinical contract research organization (now a subsidiary of Charles River Labs). There are no arrangements or understandings between Mr. Oakley and any other persons to which he was elected as an officer and Mr. Oakley has no family relationships with any other director or executive officer of the Company.
Item 7.01 Regulation FD Disclosure.
On February 15, 2019, the Company issued a press release regarding Mr. Oakley’s election. A copy of the press release is furnished as Exhibit 99.1 to this report. Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| ExhibitNo. | Description |
| 99.1 | Press Release, dated February 15, 2019. |
BIOANALYTICAL SYSTEMS INC Exhibit
EX-99.1 2 tv513941_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE FOR MORE INFORMATION: Company Contact: Jill C. Blumhoff Chief Financial Officer Phone: 756.497.8381 jblumhoff@BASinc.com BASi Appoints Senior Contract Research Executive,…
To view the full exhibit click here
About BIOANALYTICAL SYSTEMS,INC. (NASDAQ:BASI)
Bioanalytical Systems, Inc. (BASi) is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The Company operates through two segments: contract research services and research products. Its contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Its research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Its Culex family of robotic automated dose delivery, blood and other biofluids sampling and physiological parameters measurement systems enable researchers to determine pharmacokinetic/pharmacodynamic (PK/PD) profiles of drugs in large and small animal models. The Company’s bioanalytical services group supports research, preclinical and clinical programs.